Physician profile
Dharamveer Singh
NPI 1972703858
$1,335.64
in general payments reported to CMS, 2019-2025
23 companies · $684 in 2025
The $684 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.97 · 2022: $15.00 · 2023: $302 · 2024: $319 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $165.42 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Idorsia Pharmaceuticals US INC | $141.09 | 2023 | Quviviq |
| Exact Sciences Corporation | $137.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $109.63 | 2022-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.06 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Itamar Medical INC | $82.54 | 2024-2025 | Watchpatone |
| Novo Nordisk INC | $76.84 | 2023-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $73.63 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $59.30 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Vertex Pharmaceuticals Incorporated | $57.62 | 2024-2025 | |
| Abbott Laboratories | $57.27 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $47.40 | 2024-2025 | Repatha, Otezla, Repatha |
| Tosoh Bioscience, INC. | $31.96 | 2024 | Na |
| Resmed Corp | $28.21 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.52 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $21.77 | 2025 | |
| Verona Pharma, INC. | $21.16 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $20.68 | 2024 | Zerbaxa, Dificid |
| Actelion Pharmaceuticals US, INC. | $19.83 | 2025 | Opsumit, Uptravi |
| Phathom Pharmaceuticals, INC. | $16.08 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.48 | 2023 | Eliquis |
| Medline Industries LP | $14.08 | 2023 | |
| Lilly USA, LLC | $13.77 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharamveer Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.